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        Platelet concentrates (PCs) from donated blood 
are required to treat severe thrombocytopenia 
in patients with various hematological diseases, 
such as those who have undergone cancer che-
motherapy or are recovering from hemato-
poietic stem cell (HSC) transplantation (  1, 2  ). 
Frequent transfusion of PCs is clinically neces-
sary because the half-life of transfused human 
platelets is 4  –  5 d (  3  ). Platelets cannot be stored 
frozen, thus the ability to generate platelets in 
vitro would provide signifi   cant advances for 
platelet replacement therapy in clinical settings. 
A novel culture method to generate human 
platelets from cord blood CD34  +   cells was re-
cently developed as an alternative source for PCs 
(  4  ). However, technical diffi   culties in expand-
ing ex vivo  –  cultured cord blood CD34  +   cells 
on a large scale have limited this as a reasonable 
in vitro approach for generating platelets. 
  Human embryonic stem cells (ESCs) can be 
forced to diff  erentiate along a megakaryocytic 
lineage and represent a promising in vitro source 
for platelets. Owing to their pluripotency, ESCs 
can potentially proliferate indefi  nitely in culture 
(  5  ). Platelets, as anucleate fragments of cytoplasm, 
can be irradiated before transfusion to eff  ec-
tively eliminate any contaminating cell, such 
as an undiff  erentiated ESC. The possibility of 
irradiation is important, as ESCs can potentially 
form teratomas or, if present at high numbers, 
elicit an immune response (  6, 7  ). Thus, although 
ESCs represent a potentially safe and unlimited 
source of platelets in vitro, there are technical 
obstacles that remain. 
  First, culture methods for effi   cient in vitro 
generation of platelets have not been established. 
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  Embryonic stem cells (ESCs) could potentially compensate for the lack of blood platelets 
available for use in transfusions. Here, we describe a new method for generating mouse 
ESC-derived platelets (ESPs) that can contribute to hemostasis in vivo. Flow cytometric 
sorting of cells from embryoid bodies on day 6 demonstrated that c-Kit  +   integrin     IIb 
(    IIb)  +   cells, but not CD31  +   cells or vascular endothelial cadherin  +   cells, are capable of 
megakaryopoiesis and the release of platelet-like structures by day 12.     IIb    3-expressing 
ESPs exhibited ectodomain shedding of glycoprotein (GP)Ib    , GPV, and GPVI, but not 
    IIb    3 or GPIb    . ESPs showed impaired     IIb    3 activation and integrin-mediated actin 
reorganization, critical events for normal platelet function. However, the administration of 
metalloproteinase inhibitors GM6001 or TAPI-1 during differentiation increased the ex-
pression of GPIb    , improving both thrombogenesis in vitro and posttransfusion recovery in 
vivo. Thus, the regulation of metalloproteinases in culture could be useful for obtaining 
high-quality, effi  cacious ESPs as an alternative platelet source for transfusions. 
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fraction of bone marrow cells (  22  ). The     IIb integrin subunit 
is an early primitive and defi  nitive marker of hematopoiesis 
in the mouse embryo (  17, 18  ) and a lineage-specifi  c marker 
for postnatal megakaryocytes and platelets (  23  ). We reasoned 
that CD31  +  ,     IIb  +  , or c-Kit  +   cells were candidates for mega-
karyocyte progenitors derived from ESCs because postnatal 
HSCs, mature megakaryocytes, and platelets all express CD31 
and     IIb    3, and postnatal megakaryocyte progenitors express 
both c-Kit and     IIb    3 (  22  ). 
  To determine which cells actually contribute to megakaryo-
poiesis, we chose to induce a liquid culture system of ESCs for 
embryoid body (EB) formation (  24  ). Sorted cells were then ap-
plied onto OP9 stromal cells to diff  erentiate along the mega-
karyocytic lineage (  Fig. 1 A  ).   This two-stage approach was used 
because EB formation has been reported to be more suitable 
than co-culture with OP9 cells in producing hematopoietic 
progenitors in vitro (  25  ). Indeed, liquid culture for EB forma-
tion resulted in reproducibly higher expression of the     IIb inte-
grin subunit than the use of the OP9 co-culture system (  Fig. 
1 B  ) (  26  ). ESCs co-cultured with OP9 stromal cells preferentially 
expressed CD31 (  Fig. 1 B  , right) or vascular endothelial (VE)-
cadherin (unpublished data) by days 4  –  5, as reported (  27  ). 
  To trace newly developed megakaryocytes and platelets 
in culture, we generated a novel ESC line in which the plate-
let-specifi  c GPIb     promoter supports expression of a human 
GPIb      –  EGFP fusion protein (  Fig. 1 C  , GPIb-ESCs) (  28  –  30  ). 
Earlier reports showed selective expression in megakaryocytes 
and platelets using this system (  29  –  31  ). The GFP-tagged cells 
were detectable by day 9 in the presence of TPO (  Fig. 1 C  ). In 
addition, GFP expression was detectable only in     IIb  +  GPIb      +   
megakaryocytes derived from cultures treated with TPO but 
not in Ter119  +   erythroblasts isolated from erythropoietin-con-
taining cultures (not depicted). We further separated EB cells 
on day 6 to identify which fraction could diff  erentiate into 
GFP-expressing megakaryocytes (  Fig. 1 D  ). Murine ESCs (2   ×   
10  5   per 100-mm dish) typically produced 10  6   c-Kit  +      IIb  +   cells 
by day 6 and 2.5   ×   10  6       IIb  +   megakaryocytes by day 12. Cells 
derived from the c-Kit  +      IIb  +   fraction at day 6 expressed GFP 
on day 12 at 10-fold higher levels compared with cells in other 
fractions or in unfractionated whole EB-derived cells (  Fig. 
1 E  ). Fetal liver kinase (Flk)-1  +  CD31  +   or VE-cadherin  +  c-Kit  +   
cells from day 6 EB did not contribute to megakaryopoiesis in 
this system (  Fig. 1, D and E  ). ESC-derived VE-cadherin  +  c-
Kit  +  CD45        cells in OP9 co-culture had been reported to con-
tribute to defi  nitive hematopoiesis (  32  ). 
  Serial RT-PCR studies to detect GPIb     or GPV, both 
megakaryocytic-specifi  c markers (  33  ), along with the essential 
transcription factors for megakaryopoiesis, GATA-1, GATA-2, 
FOG-1, Fli-1, or NF-E2 (  34, 35  ), indicated that day 6 EB 
c-Kit  +      IIb  +   cells were positive for these markers in the pres-
ence of TPO on OP9 stromal cells (  Fig. 1 F  ) (  34  ). Indeed, day 
6 EB c-Kit  +      IIb  +   cells corresponded to CD9  +  Sca-1        cells in 
bone marrow  –  derived megakaryocyte progenitors (  Fig. 1 D  ) 
(  22  ), and their morphological features resembled immature 
hematopoietic progenitor cells derived from adult bone mar-
row (  Fig. 1 G  ) (  22  ). We concluded from these results that 
Second, appropriate in vivo function of the in vitro  –  produced 
platelet must be achieved. In addition, contamination with 
nonhuman antigens resulting in immunological reactions must 
be prevented. We and other groups have developed a method 
to generate large numbers of megakaryocytes and platelets 
from mouse ESCs grown on OP9 stromal cells in vitro (  8, 9  ). 
However, these methods have not consistently produced ESC-
derived megakaryocytes or platelets in suffi   cient quantity or 
quality to be considered as an alternative platelet source. No 
pre-selection for megakaryocyte progenitors was included in 
these previous reports. Studies have shown that the in vitro 
generation of large numbers of mature megakaryocytes de-
pends on increased numbers of ESC-obtained progenitors (  7, 8  ). 
Therefore, the identifi  cation and selection of megakaryocyte 
progenitors might increase the effi   ciency of megakaryopoiesis. 
  The functional platelet paradigm in hemostasis and throm-
bosis is the initiation of platelet adhesion to the extracellular 
matrix (  10  ). One key event in this process is the interaction 
between glycoprotein (GP)Ib     (the platelet receptor) and von 
Willebrand factor (VWF) present in the extracellular matrix 
(  10  ). Simultaneously, platelets can interact with surface-bound 
collagen via platelet receptors GPVI and integrin     2    1 (  11  ). 
The net result is an activation of integrin     IIb    3 to become a 
competent fi  brinogen receptor leading to the formation of 
platelet aggregates (  10  ). A recent report has also suggested that 
GPIb     contributes to arterial thrombosis in vivo independently 
of binding to VWF (  12  ). Indeed, other studies have demon-
strated that GPIb     associates with thrombin, kininogen, co-
agulation factors XI and XII, and thrombospondin-1 (  13  ). In 
addition, the GPIb  –  V-IX complex, consisting of GPIb    , 
GPIb    , GPIX, and GPV (  10, 14  ), can bind integrin     M    2 on 
macrophages/monocytes or P-selectin on endothelial cells (  13  ). 
Of note, aged human and mouse platelets shed GPV and an 
extracellular domain of GPIb    , which contains the binding 
sites for VWF and thrombin (  13, 15  ). This process involves the 
action of a disintegrin and metalloproteinase (ADAM)17 (also 
referred to as tumor necrosis factor      converting enzyme) (  16  ). 
This leads to decreased platelet function (  16, 17  ). 
  In this study, we demonstrate that c-Kit  +   integrin     IIb 
(    IIb)  +   cells isolated from ESCs diff  erentiate with high effi   -
ciency into megakaryocytes and ESC-derived platelets (ESPs) 
in the presence of thrombopoietin (TPO) and stromal cells. 
We also show that ESPs shed extracellular domains of GPIb    , 
GPV, and GPVI in culture, reducing     IIb    3 activation and 
actin polymerization. Consequently, these ESPs are function-
ally impaired in thrombus growth (  18, 19  ). However, the in-
hibition of metalloproteinases restores platelet function, making 
ESPs from induced pluripotent stem cells a source of platelets 
with therapeutic potential (  20, 21  ). 
    RESULTS   
  Markers defi  ning megakaryocyte differentiation from ESCs 
  The cell markers defi  ning the megakaryocytic lineage in a 
culture system of ESCs or HSCs are not understood. It is 
known that megakaryocyte progenitors are highly enriched 
in the CD9  +      IIb subunit  +   (    IIb  +  )Fc    R  lo  c-Kit  +  Sca-1       Lin        JEM VOL. 205, August 4, 2008 
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c-Kit  +      IIb  +   cells derived from ESCs can diff  erentiate display-
ing several markers unique to the megakaryocytic lineage. 
  GPIb     expression on ESPs is reduced during in vitro culture 
  EB generation from ESC in liquid culture (6 d) followed by 
sorting for c-Kit  +      IIb  +   cells (  Fig. 1 A  ) resulted in the constant 
    Figure 1.         c-Kit  +      IIb  +   cell selection from day 6 EB determines the megakaryocytic lineage.   (A) Protocol used in this study. (B) EB formation or 
OP9 co-culture was used for ESC differentiation from day 0 through day 6 in vitro. On the indicated days of culture, expression of Flk-1, integrin    IIb 
subunit (CD41), or CD31 was examined in both groups of cultured cells. The graph shows mean   ±   SEM from three independent experiments. (C) GPIb    
and GFP expression in GPIb    -ESCs is regulated by the human GPIb     promoter. GFP is detectable in cultured cells that exhibit megakaryopoiesis (day 9) 
but not in progenitors (day 6). In the bottom box, cells with surface-expressed GFP also express human GPIb    . The cells on day 9 were fi  xed and stained 
to mark human GPIb     to  confi  rm the colocalization with GFP expression at the membrane of the cells. Bars, 10   μ  m. (D) Representative dot plots for the 
expression of individual antigens on 10,000 living cells from day 6 EB. c-Kit  +   IIb +   cells corresponded with Flk-1  +   cells (not depicted) but not with VE-
cadherin  +   cells. And   >  96% of c-Kit  +   IIb +   cells are found in the CD9  + Sca-1       fraction. (E) EB cells were sorted as shown in D, and 20,000 cells per well of a 
6-well plate were seeded onto OP9 stroma cells in the presence of TPO. The left graph shows the number of generated GFP  +   cells (mean   ±   SEM) per well 
of a 6-well plate on day 12 of culture. Representative images from day 12 culture dishes (phase or fl  uorescence microscopy [insets: bar, 50   μ  m] of four 
different fraction-derived cells at day 6; i, c-Kit  + /  IIb + ;  ii,  c-Kit     /  IIb +  ; iii, c-Kit  + /  IIb      ; iv, c-Kit      /  IIb       [phase: bar, 50   μ  m]) and of Wright-Giemsa  –  stained 
cytospin preparation on day 12 derived from c-Kit  + /  IIb +   fraction of day 6 were also shown. Bar, 50   μ  m. Results indicate that c-Kit  + /  IIb +   fraction of day 
6 (i) selectively yields megakaryocytes on day 12. Similar results have been obtained from three independent experiments. (F) Expression of genes related 
to the megakaryocytic lineage as determined by RT-PCR of cells from day 0, 6, or 8 cultures as indicated. (G) Wright-Giemsa  –  stained cytospin preparation 
of sorted c-Kit  +   IIb +   cells from EB at day 6 is shown. Bar, 10   μ  m.     
generation of megakaryocytes and platelet-like particles, an im-
provement over our previously reported culture conditions (  9  ). 
After 8  –  14 d in culture (2  –  8 d on co-culture with OP9 stromal 
cells), culture supernatants contained proplatelets (  Fig. 2 A  , i) 
and platelet-sized particles consistent with ESPs (  Fig. 2 B  ).   
The granularity and size of these ESPs varied from those of 1920 METALLOPROTEINASE REGULATION IN ESC-DERIVED PLATELETS   | Nishikii et al. 
  ADAM17 can cleave the extracellular domain of GPIb     
on human and mouse platelets abrogating platelet function by 
its metalloproteinase activity (  16, 17  ). Thus, we investigated 
whether a metalloproteinase supported the shedding of GPIb     
in culture. Two potent metalloproteinase inhibitors, GM6001 
(Ilomastat) or TAPI-1, were added to the co-culture system 
to evaluate the potential involvement of a matrix metallopro-
teinase (MMP). Because both inhibitors also inhibit MMP9, 
which has been reported to facilitate megakaryopoiesis (  37  ), 
the drugs were administered only after day 10 (day 4 of co-
culture) when megakaryocyte polyploidy is observed (  9  ). In-
deed, we found that the addition of GM6001 at the co-culture 
start impaired megakaryopoiesis (not depicted). GM6001 and 
TAPI-1 (  Fig. 3 B  , 1 and 10   μ  M) increased GPIb     expression 
on released ESPs at day 12 (  Fig. 3, A and B  ).   This increased 
expression did not aff  ect the total number of     IIb  +   ESPs 
(    IIb  +  GPIb      +   plus     IIb  +  GPIb           ) at days 12 (  Fig. 3 C  ) or 14 
(not depicted). But the reduction of GPIb     was not observed 
on megakaryocytes during the culture (  Figs. 2 C  , i, and 3 A). 
Similarly, GM6001 addition to the culture restored expres-
sion of GPV and GPVI in     IIb  +   ESPs (  Fig. 3 D  ) as reported 
  circulating murine platelets as determined by transmission elec-
tron microscopy (TEM) (  Fig. 2 A  ) and the forward scatter 
profi  les produced by fl  ow cytometry (  Fig. 2 B  ). Thus, the cul-
ture conditions seem to yield various developmental stages of a 
platelet (  36  ). ESPs displayed an extensive surface-connected open 
canalicular system and multiple      or dense granules (  Fig. 2 A  , 
ii and iii). As compared with a normal mouse platelet, ESPs had 
a reduced number of granules per ESP (unpublished data). 
  We examined the relative expression of receptors by fl  ow 
cytometry comparing ESPs and freshly isolated murine plate-
lets. Expression of the integrin     IIb, GPIb    , and GPIX was 
similar in platelets from the two sources (  Fig. 2 B  ). However, 
expression of GP Ib    , GPV, and GPVI was signifi  cantly less for 
ESPs as compared with mouse platelets (  Fig. 2 B  ). Cells with 
an     IIb  +  GPIb           GPIb      +   phenotype composed 35  –  65% of the 
cellular population after 12  –  14 d in culture. Reduced GPIb     ex-
pression of ESPs was not detected at day 8 (  Figs. 2 C  , i and ii), 
consistent with a longer time in culture leading to a loss of 
GPIb      +   cells or shedding of GPIb     from the cell. Unlike ESPs, 
ESC-derived megakaryocytes did not exhibit reduced GPIb     
expression, even when cultured for   >  8 d (  Fig. 2 C  , i). 
    Figure 2.         GPIb     expression is reduced on cultured ESPs but not megakaryocytes.   (A) On day 12 of the culture, ESC-derived megakaryocytes bear-
ing proplatelets are represented in panel (i) (phase contrast image in culture dish). Bar, 100   μ  m. Panels (ii) and (iii) show TEM images of ESPs. The subcel-
lular structure of ESPs showed an open canalicular system, dense granules (arrowhead), and      granules (arrow), which were similar to those of peripheral 
blood platelets. Bars, 1   μ  m. (B) Mouse platelets (12 wk old) or ESPs (day 12) were subjected to fl  ow cytometry. Graphs show representative forward scatter 
(FSC) or side scatter (SSC) dot plots. ESPs vary in size compared with mouse platelets. The remaining six graphs show surface expression of    IIb  integrin 
subunit, GPIb   ,  GPIb   , GPV, GPVI, and GPIX on mouse platelets (red lines) or ESPs (blue lines) with control IgG (black lines). (C) (i) On the indicated days of 
culture (x axis), expression of GPIb     and  GPIb    in    IIb +   megakaryocytes derived from ESCs and ESPs is shown. Panel (ii) shows the number of    IIb +   ESPs 
on days 8 and 12 that are either GPIb    +   (black bar) or GPIb          (white bar). All results are mean   ±   SEM from four independent experiments.     JEM VOL. 205, August 4, 2008 
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nexin V binding and P-selectin expression in the absence or 
presence of GM6001. Annexin V is a marker of platelet acti-
vation that detects the translocation of phosphatidylserine to 
the outer membrane, while P-selectin expression is a hall-
mark marker of activation (  13, 39  ). Annexin V binding, but 
not P-selection expression, was inhibited in the presence of 
GM6001 (  Fig. 3 F  ). These data indicate that metalloprotein-
ase-dependent cellular changes occurring during ESP genera-
tion leads to a reduced viability of these cells. Comparable 
results were obtained using a variety of diff  erent murine ESC 
lines (R1, EB3, TT2, or E14.1; unpublished data). 
  Inhibition of metalloproteinase activity restores integrin 
    IIb    3 bidirectional signaling in ESPs 
  To explore whether metalloproteinases induce extracellular 
shedding of GPIb     and aff  ect     IIb    3 inside-out signaling, we 
used fl  ow cytometry to assess specifi  c fi  brinogen binding upon 
agonist stimulation (  9  ). GM6001 restored specifi  c fi  brinogen 
for aged blood platelets (  15, 38  ). These results suggest that 
metalloproteinase(s) impairs the retention of GPIb    , GPV, 
and GPVI on ESPs. Biochemical analysis confi  rmed that ESPs 
in culture shed the extracellular domain of GPIb    , referred to 
as   “  glycocalicin  ”   (GC), in the absence of GM6001 but not in 
the presence of GM6001 (  Fig. 3 E  ). As ESC-derived meg-
akaryocytes do not show receptor shedding (  Fig. 3, A and 
E  , i), we removed them from the day 12 cell culture population. 
The remaining specimens were centrifuged, and pellets along 
with the corresponding supernatant were analyzed. Western 
blot analysis revealed GPIb     and GC antigen in the absence of 
GM6001, but a single band of GPIb     alone in the presence 
of GM6001 (  Fig. 3 E  , ii). A single band of GC was detect-
able only in the absence of GM6001 in ESP-derived super-
natant (  Fig. 3 E  , iii). 
  To study whether pre-activation by plasma membrane 
injury or the activation state of ESPs is associated with metal-
loproteinase activity during culture, we examined the an-
    Figure 3.         Inhibition of metalloproteinases in culture restores GPIb     expression in ESPs.   (A) On day 10 of ESC culture, 1% DMSO alone (vehicle) 
or 100   μ  M GM6001 dissolved with 1% DMSO was added to the culture medium. On day 12 of culture, representative fl  ow cytometry dot plots of mature 
megakaryocytes derived from ESCs (ESC-MKs) in the absence of GM6001 (left) and ESPs in the absence or presence of GM6001 are shown. (B) The graph 
shows the percentage of GPIb    +   of all    IIb +   ESPs on day 12 in the absence or presence of 1  –  10   μ  M TAPI-1 or 100   μ  M GM6001. Results are shown as 
mean   ±   SEM from three independent experiments. (C) The graph summarizes total numbers of    IIb +   (  IIb + GPIb   +   plus    IIb + GPIb        ) ESPs per well of a 6-
well plate on day 12. Results are the mean   ±   SEM from four independent experiments. (D) The graph shows the effects of the metalloproteinase inhibitor 
GM6001 on the surface expression of GPV or GPVI in    IIb +   ESPs on day12. Results are mean   ±   SEM from four independent experiments. (E) Expression of 
GPIb     or GC in lysates from ESC-MKs (i), in lysates from pellets containing ESPs depleted of MKs (ii), or in supernatant (iii). In panel (i) or (ii), lysates were 
analyzed by Western blot (7.5% SDS-PAGE) with an anti-GPIb     antibody. In panel (iii), supernatant derived from culture media of ESPs pretreated with or 
without GM6001 were subjected to immunoprecipitation followed by immunoblotting with anti-GPIb    . In vitro  –  aged platelets from an adult mouse were 
used as a positive control in panel (iii). Similar results were obtained from three independent experiments. (F) The graphs show the percentage of positive 
cells of annexin V or P-selectin from the total    IIb +   ESPs on day 12 in the absence or presence of GM6001. Results are the mean   ±   SEM from three inde-
pendent experiments.     1922 METALLOPROTEINASE REGULATION IN ESC-DERIVED PLATELETS   | Nishikii et al. 
expressed GFP in culture. GM6001-treated ESPs were trans-
fused into the tail veins of mice with signifi  cant thrombocy-
topenia (    10  4  /  μ  l) as a result of irradiation 10 d earlier (  Fig. 
6 A  ). 2, 24, 48, or 72 h after transfusion, whole blood was 
obtained from recipient mice, and the percentage of GFP-
expressing platelets among all     IIb  +   platelets was determined. 
binding when washed ESPs were stimulated with thrombin 
or ADP (  Fig. 4 A  ).   To rule out the possibility that metallo-
proteinases directly impair integrin structure in ESPs, MnCl  2   
was also used (  40  ). Binding of Alexa 488  –  conjugated fi  brino-
gen to ESPs was comparable in the presence or absence of 
GM6001 (  Fig. 4 A  ) and similar to that in blood platelets (not 
depicted). Moreover,    IIb    3-based actin cytoskeletal changes 
(outside-in signaling) of ESPs in culture were unexpectedly 
enhanced in the presence of GM6001, apparent when lamelli-
podia formation was facilitated by the addition of thrombin 
(  Fig. 4 B  , arrow). To address whether our observation of de-
fects in ESPs also applied to blood platelets, we generated in 
vitro  –  injured human platelets by incubation at 37  °  C for 24 h. 
Reduced GPIb     expression was determined by fl  ow cytom-
etry and Western blot analysis (unpublished data), and a defect 
in lamellipodia formation in these aged platelets was ob-
served. Impaired lamellipodia formation, apparent even upon 
thrombin stimulation, in aged human platelets was partially 
restored by the administration of GM6001 in culture for 24 h 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20071482/DC1). These data demonstrate that deregu-
lated     IIb    3-mediated bidirectional signaling (both inside-
out and outside-in) may be associated with an increase in 
metalloproteinase activity in both ESPs and human platelets. 
  Metalloproteinases may regulate thrombus formation under 
fl  ow conditions and posttransfusion recovery in vivo by ESPs 
  Thrombus formation is a dynamic process, and we sought to 
examine platelet function under physiologically relevant con-
ditions found in the arterial circulation. An experimental sys-
tem frequently used to study platelet thrombus formation is 
perfusion of whole blood over a monolayer of collagen at 
high shear rates, features mimicking those that occur in vivo 
(  41  ). In this model, the initial event is tethering of platelets 
via binding of GPIb     to VWF, the latter being immobilized 
by collagen (  10, 11, 13, 14  ). Direct interaction between inte-
grin     2    1/GPVI on platelets and collagen follows (  10  ). We 
prepared reconstituted whole blood consisting of mouse 
blood labeled with mepacrine, as a marker for platelets (green 
fl  uorescence), mixed (1,000:1) with Ds-red  –  labeled ESC-
derived ESPs (red fl  uorescence). As a control, washed mouse 
platelets labeled with PE-conjugated anti-    IIb antibody were 
used (  Fig. 5 A  ) (  42  ).   ESPs pretreated with 1% DMSO failed 
to adhere to collagen-VWF matrices, but pretreatment with 
GM6001 improved adhesion (  Fig. 5, B and C  ). Most impor-
tantly, treating ESPs with GM6001-treated ESPs increased 
their ability to participate in thrombogenesis. However, their 
thrombus-forming potential was less than that of uninjured 
fresh platelets derived from adult mice (  Fig. 5 C  ). 
  Aged or injured platelets are cleared out of the body after 
being trapped in the liver (unpublished data) and spleen (  43  ). 
To confi  rm the eff  ect of GM6001 on in vivo function of 
ESPs, we examined the time course kinetics of residual ESPs 
after transfusion. Because murine platelets do not express Ly5 
antigen, we chose GFP-expressing ESCs for in vivo assays af-
ter transfusion (  Fig. 6 A  ).   More than 80% of ESPs on day 12 
    Figure 4.         Inhibition of metalloproteinases is required for platelet 
function mediated through integrin     IIb    3 in ESPs.   (A) (i) Represen-
tative fl  ow cytometry dot plots showing three mM MnCl  2 -stimulated  or 
0.1 U/ml thrombin-stimulated fi  brinogen binding to integrin    IIb  3  in 
ESPs after pretreatment with 1% DMSO as a vehicle or 100   μ  M GM6001. 
(ii) The graphs show specifi  c fi  brinogen binding to    IIb   3 stimulated with 
3 mM MnCl  2   (reference   40  ), 0.1 U/ml thrombin, or 500   μ  M adenosine 
diphosphate. The value of control (vehicle) is defi  ned as 100%. Results are 
the mean   ±   SEM from three independent experiments. (B) On day 14 of 
culture, washed ESPs pretreated with 1% DMSO or 100   μ  M GM6001 were 
plated on fi  brinogen-coated coverslips for 45 min. An aliquot of each 
preparation was assayed in the presence of 1 U/ml thrombin. Cells were 
fi  xed, permeabilized, and stained with Alexa 488  –  phalloidin to stain 
F-actin (green) and with an anti-    IIb antibody followed by Alexa 567 
(red). Bar, 10   μ  m. The value of control (vehicle) is defi  ned as 100%. The 
right graph summarizes three independent experiments (mean   ±   SEM).     JEM VOL. 205, August 4, 2008 
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complex on ESPs; and (d) both inside-out and outside-in sig-
naling of     IIb    3 might be associated with metalloproteinase 
activity. A link between metalloproteinase regulation and 
    IIb    3-mediated signaling has not been reported previously. 
Preventing shedding of the     -subunit of the GPIb  –  V-IX 
complex retains key binding sites for VWF, thrombin, coagu-
lation factors, P-selectin, and Mac-1, all potentially important 
for normal platelet function (  13  ). The N-terminal motif of 
GPIb     is essential for arterial thrombosis independent of VWF 
(  12  ), and the signaling cascade from the GPIb  –  V-IX complex 
to     IIb    3 is well known to regulate integrin activation (  45  ). 
However, the mechanisms whereby metalloproteinase activ-
ity regulates integrin signaling remain to be identifi  ed. 
  Metalloproteinases are functionally regulated by endog-
enous inhibitors, the tissue inhibitors of metalloproteinases 
(TIMPs) (  46  ). When we considered the reason why mega-
karyocytes maintained GPIb     in culture, as opposed to ESPs, 
we hypothesized that TIMP-3, also known to inhibit ADAM17 
(  47  ), might be highly expressed in megakaryocytes but not in 
No diff  erence in the size of endogenous platelets and ESPs 
transfused into recipient mice was observed (not depicted), 
suggesting that the in vivo circulation that may induce shear 
stress is an important determinant of platelet size (  44  ). Prein-
cubation with GM6001 consistently increased the percentage of 
GFP  +   ESPs after transfusion compared with controls (  Fig. 6 B  ). 
    DISCUSSION   
  This study has shown that (a) GPIb    , GPV, and GPVI, but 
not integrin     IIb    3 or GPIb    , are shed from ESPs during 
culture; (b) the process is specifi  c for ESPs and not relevant for 
megakaryocyte diff  erentiation from ESCs; (c) the use of a me-
talloproteinase inhibitor retains the complete GPIb  –  V-IX 
    Figure 5.         ESPs treated with GM6001 but not without GM6001 
contribute to thrombus formation under fl  ow conditions.   (A)  Schema 
of the experimental design. (B) Representative two-dimensional fl  uo-
rescence images at 6 min. Glass slides coated with type I collagen were 
perfused at a wall shear rate of 1,500 s     1   for 6 min. Samples included 
reconstituted whole blood composed of ESPs (red, arrowheads) in blood 
obtained from 10  –  12 mice (per experiment), or a mixture of PE-labeled 
mouse platelets (red, arrowheads) in whole blood pooled from 10  –  12 
mice. All murine platelets or ESPs were stained with mepacrine (green). 
ESPs capture fl  uorescent mepacrine as indicated by their dual expression 
of green and red by fl  ow cytometer. Bars, 100   μ  m. (C) After 6 min, platelet 
thrombi formed on the collagen surface were quantifi  ed using NIH 
Images software from a recorded video. The results summarize four 
independent experiments (mean   ±   SEM).     
    Figure 6.         The effect of metalloproteinase inhibition on posttrans-
fusion recovery by ESPs in mice.   (A) Schema of the experimental de-
sign. (B) 2 h after transfusion of 3   ×   10  6   ESPs, using a 129Ola strain 
mouse model in which platelet numbers are severely reduced, blood ob-
tained from the retroorbital venous plexus was treated with 3.8% sodium 
citrate and subjected to fl  ow cytometry to detect GFP  +   platelets  (ESPs) 
among all    IIb +   platelets. Additional serial evaluations were performed 
24, 48, and 72 h after transfusion. Pretreatment with GM6001 increased 
the ratio of GFP  +   ESPs per a recipient at all points examined. Results are 
the mean   ±   SEM from three independent experiments.     1924 METALLOPROTEINASE REGULATION IN ESC-DERIVED PLATELETS   | Nishikii et al. 
  MATERIALS AND METHODS 
  Plasmid preparation, reagents, and mice.     All reagents were purchased 
from Sigma-Aldrich unless otherwise indicated. All animal and recombinant 
DNA experiments were approved by the Institutional Animal Care and Use 
Committee of the Institute of Medical Science, University of Tokyo. C57BL/6 
mice were purchased from SLC. 129Ola mice (transfusion recipients) were 
purchased from The Jackson Laboratory.   MMP9      /        mice were provided by 
Z. Werb (University of California, San Francisco, San Francisco, CA) (  45  ). 
Rhodamine- and Alexa 488  –  conjugated phalloidin, Alexa 488  –  conjugated 
fi  brinogen, Alexa 568  –  conjugated bovine IgG, and Alexa 647  –  conjugated 
mouse IgG antibodies were from Invitrogen. Purifi  ed human fi  brinogen was 
from American Diagnostica Inc. FITC- and allophycocyanin (APC)-conju-
gated, PE-conjugated, and unconjugated anti  –  mouse integrin     IIb subunit 
and APC-conjugated anti  –  c-Kit, PE-conjugated anti-CD31, PE-conjugated 
anti  –  Sca-1, biotin-conjugated anti-CD9, FITC-conjugated anti  –  P-selectin, 
unconjugated human anti-GPIb    , and streptoavidin-APC  –  cyanine 7 (APC-
Cy7) antibodies were from BD Biosciences. An annexin V  –  FITC apoptosis 
detection kit was purchased from BD Biosciences. PE-conjugated or uncon-
jugated anti  –  mouse GPIb    , FITC-conjugated anti  –  mouse GPIb    , GPV, 
GPVI, and GPIX antibodies were from Emfret. Biotin-conjugated anti  –  VE-
cadherin antibody was provided by M. Ogawa (Kumamoto University, Ku-
mamoto, Japan). Human TPO and erythropoietin were provided by H. 
Miyazaki (Kirin, Takasaki, Japan). Mouse leukemia inhibitory factor 
(  R  ESGRO) was from Millipore. Human TPO, IL-6, and IL-11 were pur-
chased from PeproTech. GM6001 and TAPI-1 (  57  ) were from EMD. 
  Growth and diff  erentiation of ES cells.     The murine ESC lines E14tg2A 
(  58  ), E14 (  5  ), R1 (  8  ), EB3 (  37  ), and TT2 (  7  ) were maintained as described 
previously (  9  ). For EB formation, 2   ×   10  5   ESCs were placed in 100-mm 
bacterial Petri dishes containing Iscove  ’  s modifi  ed Dulbecco  ’  s medium sup-
plemented with a cocktail of 300   μ  g/ml human transferrin, 0.45 mM mono-
thioglycerol, 50  μ  g/ml ascorbic acid, and penicillin-streptomycin/ l-  glutamine 
solution (Invitrogen). On day 5 or 6 of culture, cells were dissociated with 
0.25% trypsin/EDTA and subjected to sorting by FACS MoFlo (Dako). 
Sorted cells (2   ×   10  4   per well) were seeded onto OP9 stroma cells in 6-well 
plates with 20 ng/ml TPO as described previously (  9  ). After 3 d of culture, 
a cocktail of 10 ng/ml TPO, 5 ng/ml IL-6, and 10 ng/ml IL-11 was added. 
Cell surface antigen expression was examined by fl  ow cytometry (FACS 
Aria; BD Biosciences). 
  Establishment of GPIb-ESC line.     An expression construct containing a 
human genomic DNA fragment containing the   GPIb       promoter (  28  ), fol-
lowed by coding sequence for a human   GPIb      –    –  EGFP   fusion, was inserted 
into pcDNA 3.1 (+)/zeo vector (Invitrogen). All sequences were subse-
quently confi  rmed by nucleotide sequencing. Completed pcDNA3.1 zeo 
vector was linearized with NheI site and transfected into E14tg2A ESCs by 
electroporation. After drug selection with 65   μ  g/ml zeocin for 7 d, resistant 
colonies were collected. Viable ESCs were confi  rmed by PCR to detect 
  zeocin   and human   GPIb      –  EGFP   as a positive clone. To defi  ne useful ESC 
clones further, the intensity of GFP expression was assessed after diff  erentia-
tion into megakaryocytes (  Fig. 1 C  ). 
  Quantifi  cation by RT-PCR.     Sorted cells from day 6 EB or day 8     IIb  +  c-
Kit        megakaryocytes cultured on OP9 were lysed with Trizol-LS (Invitro-
gen) for total RNA extraction. cDNAs were obtained by using Thermo 
Script RT-PCR System and oligo-dT primer (Invitrogen). Final results 
were normalized with intrinsic GAPDH and PCR Taqman PCR probe in 
quantity (Applied Biosystems). RT-PCR was performed to determine ex-
pression levels of genes of interest. Amplifi  cation proceeded for 30  –  39 cy-
cles. PCR products were separated on agarose gels and visualized by ethidium 
bromide staining. The primer sets used are shown in Table S1, which is 
available at http://www.jem.org/cgi/content/full/jem.20071482/DC1. 
  ESP preparation and TEM study.     Platelets in culture supernatant were 
gently collected. Acid citrate dextrose solution was added to yield fi  nal 
platelets (  48  ). We therefore determined TIMP-3 expression in 
ESC-derived megakaryocytes and ESPs, but found no signifi  -
cant diff  erence by RT-PCR (unpublished data). Alternatively, 
receptor shedding may be occurring with megakaryocytes but 
is not detectable owing to their gene and protein expression po-
tential, which diff  ers from the anucleate platelet (  49  ). 
  Another interesting observation was that an administration 
of GM6001 or TAPI-1 from the beginning of culture im-
paired the production of c-Kit  +      IIb  +   cells by day 6 of the liq-
uid culture (unpublished data). We observed that the use of 
inhibitors to metalloproteinases, which cover both MMPs and 
ADAMs, is advantageous for the production of effi   cacious 
platelets only after day 10 of co-culture. Nonspecifi  c inhibition 
to metalloproteinases may aff  ect the early phase of hematopoi-
esis from ESCs as demonstrated in postnatal hematopoiesis 
through MMP9-mediated mechanisms (  50  ). In addition, it has 
been reported that MMP2 or MMP9 may have an eff  ect on 
platelet function. MMP2 activates platelet aggregation through 
an increase in phospholipase C, protein kinase C, Ca  2+   mobili-
zation, and phosphatydylinositol 3 kinase (  46, 51, 52  ). MMP9 
blocks phospholipase C, protein kinase C, Ca  2+   mobilization, 
and thromboxane A2 production leading to the inhibition of 
the eff  ects of MMP2 (  46, 52, 53  ). Integrins share some of these 
pathways and therefore might explain how both metallopro-
teinases and integrin activation might infl  uence each other. In 
a search for specifi  c MMPs regulating platelet function, we 
analyzed mice defi  cient in MMP9 and found comparable 
platelet numbers, integrin activation, and platelet spreading on 
fi  brinogen comparing wild-type and MMP9-defi  cient mice 
(Fig. S2, A, C, and D, available at http://www.jem.org/cgi/
content/full/jem.20071482/DC1). In addition, extracellular 
shedding of GPIb     was observed using in vitro  –  injured plate-
lets from  MMP9      /        mice as well as platelets from  MMP9  +/+     
mice (Fig. S2 B). These results indicate that MMP9 per se is 
not implicated in thrombopoiesis and platelet function. 
  Our results suggest that the administration of metallopro-
teinase inhibitors prolongs the half-life of circulating ESPs 
in vivo (  Fig. 6  ), presumably by maintaining the repertoire 
of membrane receptors, such as GPIb  –  V-IX and GPVI. In pa-
tients with thrombocytopenia, platelet destruction is propor-
tional to plasma concentrations of GC, a shedding product that 
includes the N-terminal domain of GPIb     (  54  ). The ecto-
domain of GPIb    , GPV, and GPVI is easily shed in stocked 
human PCs possibly due to increased activities of ADAM17 
and ADAM10 (  12, 13, 55  ). Consistent with our study, GM6001 
has been recently shown to prevent inactivation of refrigerated 
platelets by inhibiting ADAM17 activity (  56  ). Specifi  c inhibition 
to ADAM17 (and ADAM10) with spatial-temporal regulation 
not aff  ecting hematopoiesis in ESCs may increase generation 
and storage of effi   cacious ESPs. 
  In conclusion, the inhibition of metalloproteinases in mu-
rine cultures of ESC-derived c-Kit  +      IIb  +   primitive cells repre-
sents an improvement in the production of effi   cacious ESPs. 
Confi  rming these observations starting with human cells is a fu-
ture direction potentially defi  ning an experimental framework 
to produce ESPs in suffi   cient quantity for clinical application. JEM VOL. 205, August 4, 2008 
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10 d beforehand. To detect GFP-expressing ESPs at the indicated time 
points, blood samples were collected with micro-capillaries from the retro-
orbital venous plexus and stained with APC-conjugated anti-    IIb antibody. 
The percentage of GFP  +   ESPs was determined by fl  ow cytometry for 
each specimen. 
  Statistical analysis.     Diff  erences between experimental and control results 
(mean   ±   SE median) were analyzed by Student  ’  s   t   test. Probability values of 
P   <   0.05 were considered signifi  cant. 
  Online supplemental material.     Table S1 depicts the primers for   Fig. 1 F  . 
Fig. S1 shows the eff  ects of GM6001 on the spreading of aged human plate-
lets on fi  brinogen. Fig. S2 shows the platelet number and functions via an 
integrin bidirectional signaling in  MMP9      /        mice and their control  MMP9  +/+     
mice. The online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20071482/DC1. 
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sion electron microscope operating at 80 kV (JOEL). Specimens were treated 
with a mixture of 0.5% glutaraldehyde and 2% paraformaldehyde, followed 
by 1% osmium tetroxide for observation. 
  Biochemical studies.     For immunoprecipitation, lysis buff  er (2% Triton 
X-100 or 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 0.5 mM 
EGTA, 0.5 mM EDTA, 1 mM Na  3  VO  4  , 0.5 mM NaF, 0.5 mM PMSF, and 
50   μ  g/ml leupeptin) was used. Separated supernatant in culture at day 12 of 
culture was immunoprecipitated with anti-GPIb     antibody and immuno-
blotted with anti-GPIb     antibody (clone Xia G7). 
  Integrin activation and actin cytoskeletal changes.     To investigate in-
tegrin     IIb    3 activation, 50-  μ  l aliquots of ESPs were incubated with APC-
conjugated anti-    IIb and 200   μ  g/ml Alexa 488  –  fi  brinogen in the absence or 
presence of thrombin or ADP for 30 min at room temperature. Binding of 
Alexa 488  –  fi  brinogen to ESPs was quantifi  ed using fl  ow cytometry. Non-
specifi  c binding was determined in the presence of 10 mM EDTA or 20   μ  g/ml 
1B5, a specific inhibitor of mouse     IIb    3 (provided by B. Coller, The 
Rockefeller University, New York, NY). Specifi  c binding was defi  ned as 
total minus nonspecifi   c binding. To investigate outside-in signaling via 
    IIb    3, all observations of cytoskeletal changes (morphology of spreading) 
in ESPs were performed using a confocal microscopic system (TCS SP2; 
Leica) as described previously (  9  ). 
  Flow chamber study.     To study the eff  ect of inhibition on metalloprotein-
ases, reconstituted whole blood was prepared by combining ESPs and mouse 
blood. ESPs were generated from ESCs in which the CAG promoter con-
sistently controls Ds-red expression (provided by H. Niwa, RIKEN, Kobe, 
Japan) (  Fig. 5 A  ). ESPs in which red fl  uorescent protein was expressed were 
combined (1:1,000 ratio) with mouse whole blood that had been labeled 
with mepacrine to mark mouse platelets; the total volume per experiment 
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of the treated blood, containing ESPs, were injected into the chamber with 
a syringe pump (Harvard Apparatus) at a constant fl  ow rate to achieve high 
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generated in culture in the absence or presence of metalloproteinase inhibi-
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